SOD2 V16A amplifies vascular dysfunction in sickle cell patients by curtailing mitochondria complex IV activity

Area of Science:

• Biochemistry
• Genetics
• Cardiovascular Medicine

Background:

• Superoxide dismutase 2 (SOD2) protects mitochondria from oxidative damage.
• A common SOD2 variant (V16A) in the mitochondrial leader sequence is found in sickle cell disease (SCD) patients.
• The cardiovascular impact of SOD2V16A in SCD remains unclear.

Purpose of the Study:

• To investigate the cardiovascular consequences of the SOD2V16A variant in SCD patients.
• To determine the effect of SOD2V16A on endothelial cell function and mitochondrial activity.

Main Methods:

• Analysis of cardiovascular parameters (TRV, blood pressure, RV size, 6MWD) in 410 SCD patients.
• Biochemical assays to measure oxidative stress markers (LDH).
• In vitro studies using endothelial cells with introduced SOD2V16A variant to assess ROS production, mitochondrial respiration, and complex IV activity.

Main Results:

• SOD2V16A associated with increased TRV, systolic blood pressure, right ventricle area, and decreased 6-minute walk distance in SCD patients.
• Elevated plasma LDH correlated with higher TRV.
• SOD2V16A increased ROS production in endothelial cells, linked to decreased mitochondrial complex IV activity and respiration, not mislocalization.

Conclusions:

• SOD2V16A is a potential biomarker for cardiovascular dysfunction in SCD.
• The variant exacerbates oxidative stress and impairs mitochondrial complex IV function in endothelial cells, contributing to cardiovascular complications in SCD.